Biography
Carin A. Uyl-de Groot studied Health Care Policy and Management at the Erasmus University Rotterdam. From March 1990 onwards she is working at the institute for Medical Technology Assessment/Department of Health Care Policy and Management at the Erasmus Medical Centre Rotterdam. Her research activities are mainly focused on cost-effectiveness analyses of cancer treatments. Quality of life studies are an integral part of these studies. From 1994 she is program leader of cancer studies. Her main interest consists of diagnostics and therapeutic technologies, economic studies linked to clinical studies, modelling studies, cost studies, quality of life studies, methodological issues and implementation studies particularly in the cancer field. She got her PhD in 1995. Since March 2000 she is director of the institute for Medical Technology Assessment. Since November 2005 she has been appointed professor of health technology assessment at the VU University Medical Center in Amsterdam.
Erasmus School of Health Policy & Management
Full professor | Health Technology Assessment (HTA)
- uyl@eshpm.eur.nl
- Room
- J8-35
- Location
- Burg. Oudlaan 50, Rotterdam
More information
Work
- Nitzan Burrack, Laura A. Hatfield, Pieter Bakx, Amitava Banerjee, Yu Chin Chen, Christina Fu, Carlos Godoy Junior, Michal Gordon, Renaud Heine, Nicole Huang, Dennis T. Ko, Lisa M Lix, Victor Novack, Laura Pasea, Feng Qiu, Therese A Stukel, Carin de Groot, Bheeshma Ravi, Saeed Al-Azazi, Gabe Weinreb, Peter Cram & Bruce E. Landon (2023) - Variation in care for patients presenting with hip fracture in six high-income countries: A cross-sectional cohort study - Journal of the American Geriatrics Society - doi: 10.1111/jgs.18530 - [link]
- Dianne Bosch, Malou C.P. Kuppen, Metin Tascilar, Tineke J. Smilde, Peter F.A. Mulders, Carin A. Uyl-de Groot & Inge M. van Oort (2023) - Reliability and Efficiency of the CAPRI-3 Metastatic Prostate Cancer Registry Driven by Artificial Intelligence - Cancers, 15 (15) - doi: 10.3390/cancers15153808 - [link]
- Nicolas S.H. Xander, W. Edward Fiets & Carin A. Uyl-de Groot (2023) - Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands - Frontiers in Oncology, 13 - doi: 10.3389/fonc.2023.1205700 - [link]
- Marianne Luyendijk, Otto Visser, Hedwig M. Blommestein, Ignace H.J.T. de Hingh, Frank J.P. Hoebers, Agnes Jager, Gabe S. Sonke, Elisabeth G.E. de Vries, Carin A. Uyl-de Groot & Sabine Siesling (2023) - Changes in survival in de novo metastatic cancer in an era of new medicines - Journal of the National Cancer Institute, 115 (6), 628-635 - doi: 10.1093/jnci/djad020 - [link]
- Lj Bakker, Fw Thielen, Wk Redekop, CA Uyl de Groot & Hm Blommestein (2023) - Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma - BMC Medical Research Methodology, 23 (1) - doi: 10.1186/s12874-023-01952-2 - [link]
- Anna M. Smak Gregoor, Tobias E. Sangers, Lytske J. Bakker, Loes Hollestein, Carin A. Uyl – de Groot, Tamar Nijsten & Marlies Wakkee (2023) - An artificial intelligence based app for skin cancer detection evaluated in a population based setting - npj Digital Medicine, 6 (1) - doi: 10.1038/s41746-023-00831-w - [link]
- Remziye Zaim, Ken Redekop & Carin A Uyl-de Groot (2023) - Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment - Frontiers in Health Services, 3 - doi: 10.3389/frhs.2023.1034256
- Remziye Zaim, W. Ken Redekop & Carin A. Uyl-de Groot (2023) - Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer - Frontiers in Oncology, 13, 1027659 - doi: 10.3389/fonc.2023.1027659 - [link]
- Remziye Zaim, Ken Redekop & Carin A Uyl-de Groot (2023) - Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer - Journal of Cancer Policy, 35 - doi: 10.1016/j.jcpo.2022.100382
- Marianne Luyendijk, Hedwig Blommestein, Carin Uyl-de Groot, Sabine Siesling & Agnes Jager (2023) - Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands - JAMA network open, 6 (2) - doi: 10.1001/jamanetworkopen.2022.56170 - [link]
- Carin Uyl - de Groot, Ken Redekop, Amir Ansaripour, K. Zendehdel, N. Tadayon & F. Sadeghi (2016) - Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran
Cie Beoordeling Oncologische Middelen
- Start date approval
- juli 2022
- End date approval
- juli 2025
- Place
- UTRECHT
Gezondheidsraad
- Start date approval
- juli 2022
- End date approval
- juli 2025
- Place
- DEN HAAG
bestuurslid CPO, Erasmus Medisch Centrum
- Start date approval
- juli 2022
- End date approval
- juli 2025
- Place
- ONBEKEND
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2023
- Course Code
- GW4555M
Master Thesis Eu-HEM
- Level
- master
- Year Level
- master
- Year
- 2023
- Course Code
- GW4560M
Master Thesis HE
- Year Level
- master, master
- Year
- 2023
- Course Code
- GW4592M
Module Knowledge
- Level
- bachelor 1
- Year Level
- bachelor 1
- Year
- 2023
- Course Code
- GW114K
f